Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the talks
-
1. Streptococcus pneumoniae: serotype diversity and epidemiology
- Dr. Bambos Charalambous
-
2. Tuberculosis: new treatments in evolution
- Prof. Stephen Gillespie
-
3. Current drugs for TB treatment
- Dr. Kasha Singh
-
4. Global progress in TB vaccine development
- Prof. Helen McShane
-
5. Management of MDR and XDR TB
- Prof. Martin Boeree
-
6. Non-tuberculous mycobacterial pulmonary disease (NTM-PD)
- Prof. Jakko van Ingen
-
7. The making of an influenza pandemic
- Prof. Jonathan Van-Tam
-
8. Responding to pandemic influenza
- Prof. Jonathan Van-Tam
- Dr. Chloe Sellwood
-
9. Controlling pandemic flu
- Prof. John Oxford
-
10. The future of influenza vaccines
- Dr. Marc P. Girard
-
11. Emerging or newly discovered viral causes of acute lower respiratory tract infections worldwide
- Dr. Marietjie Venter
- Mrs. Orienka Hellferscee
-
12. RSV vaccine development
- Prof. Ruth Karron
-
13. Respiratory mycoplasmas
- Prof. Stephen Gillespie
-
14. Infection in the cystic fibrosis lung
- Dr. Stuart Elborn
-
15. The role of infection at COPD exacerbations
- Prof. Wisia Wedzicha
-
16. An overview of non-cystic fibrosis bronchiectasis
- Dr. Maeve P. Smith
-
18. Pathogen discovery in the respiratory tract
- Dr. H. Rogier van Doorn
-
19. Aspergillosis infections and the lung
- Prof. Rosemary Barnes
-
20. Parasitic lung infections: protozoa, cestodes & trematodes
- Dr. Vannan Kandi Vijayan
-
21. Parasitic lung infections: nematodes
- Dr. Vannan Kandi Vijayan
-
22. Improving respiratory diagnostics (viruses)
- Prof. David Murdoch
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Mycoplasma definitions
- Characteristics of mycoplasmas
- Human mycoplasmas
- M. pneumoniae epidemiology
- M. pneumoniae pathogenesis
- M. pneumoniae infection syndromes
- M. pneumoniae infection clinical features
- M. pneumoniae complications
- Diagnostic samples
- Mycoplasma diagnosis overview
- Growing mycoplasma
- Mycoplasma colonies
- Relative growth rates of human mycoplasmas
- Identification of mycoplasma
- Serology for mycoplasma infection
- PCR based diagnosis
- Treatment of M. pneumoniae infection
- Treatment agents of M. pneumoniae infection
- Prevention of Mycoplasma pneumoniae infection
- A new type of mycoplasma
- M. amphoriforme infection
- Genomic investigations of M. amphoriforme
- Genomics of M. amphoriforme
- Evolution of M. amphoriforme isolates
- Study of LRTI in a community setting
- Identification of M. amphoriforme in samples
- MA Found in patients with suspected viral infection
- Treatment of Mycoplasma amphoriforme
- Understanding resistance of M. amphoriforme
- Future clinical needs
- Future research questions
- Conclusions (1)
- Conclusions (2)
- Conclusions (3)
- Acknowledgements
- Thank you
Topics Covered
- Characteristics of mycoplasmas
- Human mycoplasmas
- M. pneumoniae: epidemiology, pathogenesis, infection syndromes, clinical features, complications and treatment
- Diagnosis of infection
- Growing mycoplasma
- Newly discovered M. amphoriforme: identification, genomics and treatment
- Future research
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gillespie, S. (2015, September 30). Respiratory mycoplasmas [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 1, 2024, from https://doi.org/10.69645/EAIM7489.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Stephen Gillespie is in receipt of research grants from MMRC, EDCTP, Global Alliance for TB Drug Development. Professor Gillespie’s involvements in clinical trials are supported by active and placebo drug supplies from Bayer Schering Health Care and Sanofi Aventis, while also providing support with regulatory and drug safety advice. Neither company has a managerial role within the study, however. Professor Gillespie has also provided training to senior staff at Bayer Schering Health Care.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
It's a pleasure for me
to talk to you today
about respiratory mycoplasmas.
My name's Stephen Gillespie.
I'm the Sir James Black
Professor of Medicine
at the University of St. Andrews.
0:12
In this talk, I'm going to describe
these elusive, interesting,
but enigmatic organisms.
I first of all will give you a
definition of what a mycoplasma is,
and then a quick overview
of the human mycoplasmas
that are a challenge to clinicians.
I'm going to focus
most of this talk on two
important respiratory
pathogens, mycoplasma pneumoniae
and mycoplasma amphoriforme.
Then I'll speak a little bit about
the future of mycoplasma research,
and hopefully come
to some conclusions.
0:45
Mycoplasmas and related organisms
are ubiquitous in nature,
and such organisms are found widely
in humans, animals, and plants.
We don't think much
about them as clinicians
because they're very
difficult to diagnose
because of their slow growth.
Their small cells were the
first to have a whole genome
sequenced and indeed
the first organism
to be synthesized synthetically.
So they're very small
bacteria and the smallest
capable of extracellular existence.
Their genome is also small, ranging
from 0.5 of a megabit to 2.2.
They closely adhere
to cells, and they
lack a typical bacterial cell wall.
They have no peptidoglycan.
They have an interesting
evolutionary past.
Mycoplasmas are
thought to have evolved
from gram positive bacteria,
probably clostridia,
through reductive evolution.
Both pathogens and commensals
are found in human samples.
And it can be often
challenging to differentiate
whether the organisms are acting
as commensals or pathogens.